Role of Efflux Pumps and Topoisomerase Mutations in Fluoroquinolone Resistance in Campylobacter jejuni and Campylobacter coli
Open Access
- 1 August 2005
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 49 (8) , 3347-3354
- https://doi.org/10.1128/aac.49.8.3347-3354.2005
Abstract
Point mutations in the topoisomerase (DNA gyrase A) gene are known to be associated with fluoroquinolone resistance in Campylobacter . Recent studies have shown that an efflux pump encoded by cmeABC is also involved in decreased susceptibilities to fluoroquinolones, as well as other antimicrobials. Genome analysis suggests that Campylobacter jejuni contains at least nine other putative efflux pumps. Using insertional inactivation and site-directed mutagenesis, we investigated the potential contributions of these pumps to susceptibilities to chloramphenicol, ciprofloxacin, erythromycin, and tetracycline in C. jejuni and Campylobacter coli . Insertional inactivation of cmeB resulted in 4- to 256-fold decreases in the MICs of chloramphenicol, ciprofloxacin, erythromycin, and tetracycline, with erythromycin being the most significantly affected. In contrast, inactivation of all other putative efflux pumps had no effect on susceptibility to any of the four antimicrobials tested. Mutation of gyrA at codon 86 (Thr-Ile) caused 128- and 64-fold increases in the MICs of ciprofloxacin and nalidixic acid, respectively. The replacement of the mutated gyrA with a wild-type gyrA allele resulted in a 32-fold decrease in the ciprofloxacin MIC and no change in the nalidixic acid MIC. Our findings indicate that CmeABC is the only efflux pump among those tested that influences antimicrobial resistance in Campylobacter and that a point mutation (Thr-86-Ile) in gyrA directly causes fluoroquinolone resistance in Campylobacter . These two mechanisms work synergistically in acquiring and maintaining fluoroquinolone resistance in Campylobacter species.Keywords
This publication has 47 references indexed in Scilit:
- Development of a Standardized Susceptibility Test forCampylobacterwith Quality-Control Ranges for Ciprofloxacin, Doxycycline, Erythromycin, Gentamicin, and MeropenemMicrobial Drug Resistance, 2004
- Patterns of quinolone susceptibility in Campylobacter jejuni associated with different gyrA mutationsPathology, 2004
- gyrA Polymorphism in Campylobacter jejuni : Detection of gyrA Mutations in 162 C. jejuni Isolates by Single-Strand Conformation Polymorphism and DNA SequencingAntimicrobial Agents and Chemotherapy, 2002
- Antibiotic Susceptibility Profiles of Escherichia coli Strains Lacking Multidrug Efflux Pump GenesAntimicrobial Agents and Chemotherapy, 2001
- Quinolone-ResistantCampylobacter jejuniInfections in Minnesota, 1992–1998New England Journal of Medicine, 1999
- Complete nucleotide sequence of the prophage VT2-Sakai carrying the verotoxin 2 genes of the enterohemorrhagic Escherichia coli O157:H7 derived from the Sakai outbreak.Genes & Genetic Systems, 1999
- Genes acrA and acrB encode a stress‐induced efflux system of Escherichia coliMolecular Microbiology, 1995
- EmrE, an Escherichia coli 12-kDa Multidrug Transporter, Exchanges Toxic Cations and H+ and Is Soluble in Organic SolventsJournal of Biological Chemistry, 1995
- An amplifiable and deletable chloramphenicol‐resistance determinant of Streptomyces lividans 1326 encodes a putative transmembrane proteinMolecular Microbiology, 1991
- Experimental Campylobacter jejuni Infection in HumansThe Journal of Infectious Diseases, 1988